Comparative Pharmacology
Head-to-head clinical analysis: DRAXIMAGE DTPA versus GLOFIL 125.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DRAXIMAGE DTPA versus GLOFIL 125.
DRAXIMAGE DTPA vs GLOFIL-125
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DRAXIMAGE DTPA (technetium Tc-99m pentetate) is a radiopharmaceutical that, after intravenous injection, distributes in the extracellular space and is cleared by glomerular filtration. It allows imaging of renal function and structure by emitting gamma radiation detectable by a gamma camera.
GLOFIL-125 (pentoxifylline) is a xanthine derivative that improves erythrocyte flexibility by inhibiting phosphodiesterase, leading to increased intracellular cAMP. It also reduces blood viscosity and platelet aggregation, improving microcirculation.
Diagnostic imaging: 3-5 mCi (111-185 MBq) IV for renal studies; 10-20 mCi (370-740 MBq) IV for lung perfusion imaging.
125 mg orally twice daily.
None Documented
None Documented
Terminal elimination half-life is approximately 1.6 hours (range 1.2-2.0 hours) in patients with normal renal function; prolonged in renal impairment (up to 50 hours in severe cases).
Terminal elimination half-life: 2.5–3.5 hours (prolonged in renal impairment; up to 20–30 hours in severe chronic kidney disease).
Renal: 95% within 24 hours via glomerular filtration; biliary/fecal: <5%.
Renal excretion of unchanged drug >90%; biliary/fecal <5%.
Category C
Category C
Diagnostic Radiopharmaceutical
Diagnostic Radiopharmaceutical